JOP20220339A1 - طرق وتركيبات علاج الإسهال الناتج عن العلاج الكيميائي - Google Patents
طرق وتركيبات علاج الإسهال الناتج عن العلاج الكيميائيInfo
- Publication number
- JOP20220339A1 JOP20220339A1 JOP/2022/0339A JOP20220339A JOP20220339A1 JO P20220339 A1 JOP20220339 A1 JO P20220339A1 JO P20220339 A JOP20220339 A JO P20220339A JO P20220339 A1 JOP20220339 A1 JO P20220339A1
- Authority
- JO
- Jordan
- Prior art keywords
- diarrhea
- methods
- compositions
- induced diarrhea
- treating chemotherapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
غير متوفر
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2020/038691 WO2021257089A1 (en) | 2020-06-19 | 2020-06-19 | Methods and compositions for treating chemotherapy-induced diarrhea |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20220339A1 true JOP20220339A1 (ar) | 2023-01-30 |
Family
ID=79268234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2022/0339A JOP20220339A1 (ar) | 2020-06-19 | 2020-06-19 | طرق وتركيبات علاج الإسهال الناتج عن العلاج الكيميائي |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP4168027A4 (ar) |
JP (1) | JP2023538186A (ar) |
KR (1) | KR20230027226A (ar) |
AU (1) | AU2020454132A1 (ar) |
BR (1) | BR112022025741A2 (ar) |
CA (1) | CA3182864A1 (ar) |
IL (1) | IL299028A (ar) |
JO (1) | JOP20220339A1 (ar) |
MX (1) | MX2022016367A (ar) |
WO (1) | WO2021257089A1 (ar) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115089592B (zh) * | 2022-05-21 | 2024-02-27 | 复旦大学 | 多重酪氨酸激酶在制备抑制肠道病毒71型嗜神经性病毒药物中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2777214A1 (en) * | 2009-10-06 | 2011-04-14 | The Regents Of The University Of California | Methods of treating diseases with proanthocyanidin oligomers such as crofelemer |
BR112013010774A2 (pt) * | 2010-10-31 | 2017-03-21 | Napo Pharmaceuticals Inc | "usos de crofelemer no tratamento de diarreia associada ao hiv" |
US20160067311A1 (en) * | 2014-09-10 | 2016-03-10 | Helsinn Healthcare Sa | Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea |
EP3242557A4 (en) * | 2015-01-09 | 2018-09-05 | Jaguar Health, Inc. | Methods of treating diarrhea in companion animals |
AU2017370682A1 (en) * | 2016-12-06 | 2019-06-20 | Kaleido Biosciences, Inc. | Glycan polymers and related methods thereof |
-
2020
- 2020-06-19 CA CA3182864A patent/CA3182864A1/en active Pending
- 2020-06-19 KR KR1020237002209A patent/KR20230027226A/ko unknown
- 2020-06-19 JP JP2022578560A patent/JP2023538186A/ja active Pending
- 2020-06-19 WO PCT/US2020/038691 patent/WO2021257089A1/en active Application Filing
- 2020-06-19 BR BR112022025741A patent/BR112022025741A2/pt unknown
- 2020-06-19 AU AU2020454132A patent/AU2020454132A1/en active Pending
- 2020-06-19 JO JOP/2022/0339A patent/JOP20220339A1/ar unknown
- 2020-06-19 IL IL299028A patent/IL299028A/en unknown
- 2020-06-19 MX MX2022016367A patent/MX2022016367A/es unknown
- 2020-06-19 EP EP20940856.6A patent/EP4168027A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020454132A1 (en) | 2023-02-02 |
MX2022016367A (es) | 2023-01-30 |
KR20230027226A (ko) | 2023-02-27 |
BR112022025741A2 (pt) | 2023-01-03 |
JP2023538186A (ja) | 2023-09-07 |
WO2021257089A1 (en) | 2021-12-23 |
EP4168027A1 (en) | 2023-04-26 |
EP4168027A4 (en) | 2024-04-03 |
IL299028A (en) | 2023-02-01 |
CA3182864A1 (en) | 2021-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX348184B (es) | Métodos y composiciones para tratar diarrea asociada con vih. | |
ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
MX2020009773A (es) | Terapia de combinacion. | |
WO2007130882A3 (en) | Method for treatment of diarrhea-predominant irritable bowel syndrome | |
ZA202300875B (en) | Kat6 inhibitor methods and combinations for cancer treatment | |
MX2023012095A (es) | Inhibidores de hdac6 para el uso en el tratamiento de la miocardiopatía dilatada. | |
CR20220374A (es) | Métodos de tratamiento de la esplenomegalia | |
DK1677806T3 (da) | Sammensætninger til behandling af akut og overbelastningsforårsaget forstuvning og forstrækning ved anvendelse af hyaluronsyre | |
JOP20220339A1 (ar) | طرق وتركيبات علاج الإسهال الناتج عن العلاج الكيميائي | |
MX2021004207A (es) | Uso de reboxetina para el tratamiento de narcolepsia. | |
MX2020001768A (es) | Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. | |
MX2023013403A (es) | Composicion farmaceutica para prevenir o tratar la fibrosis. | |
JOP20190276A1 (ar) | طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة | |
MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
MX2022011725A (es) | Metodos para tratar una lesion pulmonar con inhibidores de cgrp. | |
MX2023006704A (es) | Composiciones dsg2 y metodos para el tratamiento de covid-19. | |
MX2022004785A (es) | Metodos y composiciones para el tratamiento del sindrome de rett. | |
MY200960A (en) | Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury | |
MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
EA202000298A1 (ru) | ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ | |
CL2022003634A1 (es) | Métodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia. | |
WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
BR112022001814A2 (pt) | Métodos de tratamento de câncer multifocal | |
BR112022018315A2 (pt) | Regime para tratar a infecção por neisseria gonorrhoeae com gepotidacina | |
WO2020061067A3 (en) | Compositions and methods for treating bone injury |